Is Weight Loss Possible Just by Drinking? Lose 12% of Your Body Weight and Reduce Inflammation with One Pill a Day — The Impact of "Oral GLP-1"

Eli Lilly's oral GLP-1 receptor agonist, orforglipron, demonstrated an average weight loss of 12.4% (approximately 27.3 pounds) over 72 weeks in a Phase 3 trial (ATTAIN-1) published in the NEJM. About 60% of participants achieved more than 10% weight loss, and 39.6% achieved more than 15% weight loss. Improvements were also reported in prediabetes normalization, non-HDL cholesterol, systolic blood pressure, triglycerides, and CRP, which are cardiometabolic risk indicators. The side effects were mainly mild to moderate gastrointestinal symptoms. Although the "weight loss margin" is smaller compared to injectable drugs (Wegovy/Zepbound), the convenience of "one pill a day without injection" is expected to improve adherence and expand access. Meanwhile, there is uncertainty in reports regarding approval, ranging from expectations of approval within the year to projections for 2026, leading to mixed reactions in the market and on social media, with opinions divided between "highly promising" and "premature expectations."